FIBRINET
Commercial- Indications
- Lumbar fusion, Bone healing
Company intelligence / Profile preview
Royal Biologics has launched several commercial products including the BIO‑REIGN™ line of bone graft substitutes. The company’s portfolio includes advanced cellular technologies and regenerative medicine platforms focused on musculoskeletal healing and wound care. Clinical results are not detailed publicly but the company emphasizes innovation in autologous cell-based therapies and proprietary biomaterials that support cell proliferation, vascularization, and new tissue growth.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Royal Biologics.